Previous Article | Next Article 
Journal of Bacteriology, April 1999, p. 2044-2049, Vol. 181, No. 7
0021-9193/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Role of Acid pH and Deficient Efflux of Pyrazinoic Acid in Unique
Susceptibility of Mycobacterium tuberculosis to
Pyrazinamide
Ying
Zhang,1,*
Angelo
Scorpio,1,
Hiroshi
Nikaido,2 and
Zhonghe
Sun1
Department of Molecular Microbiology and
Immunology, School of Hygiene and Public Health, Johns Hopkins
University, Baltimore, Maryland 21205,1 and
Department of Molecular and Cell Biology, University of
California, Berkeley, California 947202
Received 25 November 1998/Accepted 29 January 1999
 |
ABSTRACT |
Pyrazinamide (PZA) is an important antituberculosis drug. Unlike
most antibacterial agents, PZA, despite its remarkable in vivo
activity, has no activity against Mycobacterium
tuberculosis in vitro except at an acidic pH. M. tuberculosis is uniquely susceptible to PZA, but other
mycobacteria as well as nonmycobacteria are intrinsically
resistant. The role of acidic pH in PZA action and the basis for the
unique PZA susceptibility of M. tuberculosis are unknown. We found that in M. tuberculosis, acidic
pH enhanced the intracellular accumulation of pyrazinoic acid (POA),
the active derivative of PZA, after conversion of PZA by
pyrazinamidase. In contrast, at neutral or alkaline pH, POA was mainly
found outside M. tuberculosis cells. PZA-resistant
M. tuberculosis complex organisms did not convert PZA
into POA. Unlike M. tuberculosis, intrinsically PZA-resistant M. smegmatis converted PZA into POA, but
it did not accumulate POA even at an acidic pH, due to a very active POA efflux mechanism. We propose that a deficient POA efflux mechanism underlies the unique susceptibility of M. tuberculosis
to PZA and that the natural PZA resistance of M. smegmatis is due to a highly active efflux pump. These findings
may have implications with regard to the design of new
antimycobacterial drugs.
 |
INTRODUCTION |
The antituberculosis drug
pyrazinamide (PZA) is an analogue of nicotinamide, which is a vitamin
B3 (nicotinic acid; also called niacin) precursor. The
discovery of PZA in the late 1940s as a powerful drug against
tuberculosis (TB) was based on the serendipitous observation that
nicotinamide, curiously, had activity against tubercle bacilli in
animal models (19). Subsequent synthesis of
analogues of nicotinamide led to the identification of PZA as the most
active derivative against Mycobacterium tuberculosis (12). PZA is an important component of the current 6-month
short-course TB chemotherapy. This therapy, which consists of
isoniazid, rifampin, PZA, and ethambutol and is also called DOTS (for
directly observed treatment, short-course), is recommended by the World
Health Organization for treatment of every TB patient (30).
PZA plays a unique role in shortening the therapy from a period of 9 to
12 months down to 6 months, because PZA kills a population of
semidormant tubercle bacilli, residing in an acidic environment
(occurring during active inflammation), which are not killed by other
TB drugs (6, 14). Unlike other TB drugs, PZA, despite its
remarkable activity in vivo (10), has no activity against
tubercle bacilli in vitro in normal culture medium (26)
except under acidic-pH conditions (e.g., pH 5.5) (11).
M. tuberculosis is uniquely susceptible to PZA, whose
MIC for this bacterium is about 16 to 50 µg/ml (11). In
contrast, other mycobacteria, and all nonmycobacteria, are
completely insensitive to PZA (5). In M. tuberculosis, the susceptibility to PZA correlates with the
presence of a single enzyme with nicotinamidase and
pyrazinamidase (PZase) activities (7). Strains of
M. tuberculosis that are resistant to PZA are often
defective in PZase activity (7, 9, 28), and we have
recently cloned the M. tuberculosis PZase gene
(pncA) (21) and shown that mutation of
pncA is a major mechanism of PZA resistance in M. tuberculosis (22). However, the correlation between
PZase activity and PZA susceptibility does not exist for
nontuberculous mycobacteria, since they have ample PZase activity
but are nevertheless intrinsically resistant to PZA (5, 25).
Despite the performance of many studies, the mode of action of PZA in
M. tuberculosis is unknown. Just as isoniazid requires
activation by the M. tuberculosis catalase-peroxidase (32), PZA, as a prodrug, needs to be activated by the
bacterial nicotinamidase-PZase into pyrazinoic acid (POA)
(7, 21), the active form of the drug, in bacterial cells.
Yet, the active derivative POA is not directly used to treat TB
patients, because the bactericidal activity of POA, when given orally
to mice infected with M. tuberculosis, was found to be
not as significant as that of the prodrug PZA, presumably due to poor
absorption through the gastrointestinal tract and to significant serum
binding (7). However, the reasons why PZA requires an acidic
environment to show activity and why M. tuberculosis is
uniquely susceptible to PZA were unknown. In this study, we show
that the role of acidic pH is to enhance the accumulation of
POA and that M. tuberculosis has a defective
efflux mechanism for POA whereas the naturally PZA-resistant
bacterium M. smegmatis has a much more active POA efflux mechanism.
 |
MATERIALS AND METHODS |
Chemicals and radiochemicals.
Carbonyl cyanide
m-chlorophenylhydrazone (CCCP), nigericin,
valinomycin, reserpine, N,N'-dicyclohexyl carbodiimide
(DCCD), sodium salicylate, [14C]benzoic acid, and
[14C]salicylic acid were obtained from Sigma Chemical Co.
[carbonyl-14C]PZA (specific activity, 52 mCi/mmol) was kindly supplied by the National Institutes of Health AIDS
Reagents Program, Rockville, Md. The amount of
[14C]PZA used in the various experiments was between
1 and 2 µCi/ml, which is equivalent to 2.4 to 4.8 µg of PZA/ml;
these PZA concentrations are much lower than its MIC for M. tuberculosis and are thus unlikely to cause cidal effects.
[14C]POA was generated by incubating
[14C]PZA with purified M. tuberculosis PZase, overexpressed in Escherichia coli, for about 60 min at 37°C, conditions under which
[14C]PZA was converted to [14C]POA
completely as judged by thin-layer chromatography (TLC) analysis (see below).
Effect of pH on [14C]PZA conversion and
[14C]POA accumulation in M. tuberculosis.
Late-log-phase M. tuberculosis
H37Ra cultures (2 to 3 week old), grown in 7H9 liquid medium
supplemented with albumin-dextrose-catalase, were centrifuged, and the
cells were resuspended to a density of about 5 × 109/ml in 7H9 medium adjusted to various pH values.
[14C]PZA was added to a concentration of 2.5 µCi/ml. Following incubation at 37°C for about 16 h, both the
supernatant fluids and bacterial lysates, prepared by sonication of
concentrated bacterial cells washed with phosphate-buffered saline,
were analyzed by TLC followed by autoradiography (see below). To test
the effect of pH on POA accumulation in the M. tuberculosis cells, [14C]POA was added to the
bacterial suspensions, at various pH values, at a concentration of 1 µCi/ml. At various times, 50-µl portions were removed, filtered
through 0.45-µm-pore-size nitrocellulose membranes, and washed with
0.1 M potassium phosphate buffer (pH 7.0) containing 0.1 M LiCl. In
this as well as other experiments, the radioactivity associated
with cells was measured by scintillation counting. The intracellular
concentration of POA was calculated by assuming that 1 mg of dry cells
is equivalent to 3 µl of internal water (31).
TLC.
For TLC, 2-µl portions of radioactive supernatants or
lysates were spotted onto a 0.25-mm-thick silica G gel 60 plate with an
aluminum backing (Whatman). The TLC plate was developed in 1-butanol-10% ammonia (5:1). The plate was then air dried and exposed
to X-ray film for autoradiography.
Determination of intracellular pH.
M.
tuberculosis H37Ra cells were grown in 7H9 liquid medium (pH 6.6)
to late log phase. The culture was centrifuged, and the cells were
resuspended in Sauton's medium (pH 5.0) at a density of 5 × 109/ml. POA was added to 0.4 or 4 mM (about 500 µg/ml).
Salicylate, used as a positive control, was also added to 4 mM.
Each sample was tested in triplicate. [14C]benzoic acid
or [14C]salicylic acid (Sigma Chemical Co.), as a pH
probe, was added to a final concentration of 1 µCi/ml at time zero,
50-µl portions were removed at various times and filtered through
0.45-µm-pore-size nitrocellulose membranes, and the membranes were
washed twice with 2 ml of 7H9 medium. Scintillation cocktail (3 ml) was
then added to each filter in a counting vial, and the radioactivity was
measured with a scintillation counter. The internal cell volume was
measured by using 3H2O and
[14C]taurine, and the internal pH was calculated
according to the method of Rottenberg (18).
Isolation of membrane and cytoplasmic fractions from
M. tuberculosis.
A late-log-phase culture of
M. tuberculosis H37Ra (50 ml) was harvested, and the
cells were washed twice with 40 mM potassium phosphate buffer (pH 6.5)
containing 1 mM EDTA and then resuspended in 5 ml of 40 mM potassium
phosphate buffer (pH 6.5) containing 0.3 mM phenylmethylsulfonyl
fluoride, 1,000 U of DNase I, 0.5 mg of RNase A, and 2 mM magnesium
chloride. The cell suspension (5 ml) was sonicated for 10 to 15 min on
ice and then centrifuged at 13,000 rpm for 15 min to remove large
cellular debris and unbroken cells. The supernatant was then spun at
32,000 rpm for 1 h to separate the membrane and cytosolic
fractions. The supernatant fraction (cytosolic fraction) was saved. The
pellet (membrane fraction) was washed with 40 mM potassium phosphate
buffer (pH 6.5) containing 0.3 mM phenylmethylsulfonyl fluoride and 1 mM EDTA and then dissolved in 40 mM potassium phosphate buffer (pH 6.5)
containing 1% Triton X-100. Both the supernatant and pellet fractions
were tested for PZase activity by incubating them with [14C]PZA (1 to 2 µCi) in a volume of 30 µl for
7 h, and the degree of conversion of [14C]PZA to
[14C]POA was monitored by TLC as described above.
PZA accumulation and conversion in PZA-susceptible and -resistant
M. tuberculosis complex organisms.
Two- to
3-week-old M. tuberculosis H37Ra and M. bovis BCG cultures, grown in Sauton's medium, were harvested and
then washed with Sauton's medium, and the cell pellets were
resuspended in Sauton's medium (pH 6.6) at 5 × 109
cells/ml. [14C]PZA was added to these cell
suspensions to a concentration of 1 µCi/ml, and the cell mixtures
were incubated at 37°C. At different time points, 50-µl portions
were removed and washed with Sauton's medium by filtration on
0.45-µm-pore-size nitrocellulose filters by the use of a vacuum pump.
The amount of radioactivity associated with the bacterial cells was
determined by scintillation counting.
Effect of reserpine and valinomycin on accumulation of POA in
M. smegmatis and M. tuberculosis.
[14C]PZA was added to a concentrated bacterial
suspension (5 × 109 cells/ml) in 7H9 liquid medium at
pH 6.6 to a final concentration of 2 µCi/ml. A sublethal
concentration of reserpine (20 µM) was added to the M. smegmatis cells after they had been incubated with
[14C]PZA for 1 min, allowing a substantial amount of
PZA to be taken up by the cells and converted to POA. At various times
after the addition of reserpine, 50-µl portions were removed and
spotted onto 0.45-µm-pore-size nitrocellulose membranes under a
vacuum. Because washing the M. smegmatis cells with
buffer tends to remove [14C]POA associated with the
cells, the supernatant was removed by vacuum filtration without
washing. The membrane area where the cell suspension was spotted was
cut out, and the radioactivity was determined. The effect of
valinomycin (1 µM; sublethal concentration) was determined in the
same manner, using 10 mM potassium. The effect of reserpine and
valinomycin on [14C]POA accumulation in M. tuberculosis was examined in a similar manner with the following
modifications. Reserpine (50 µM) and valinomycin (1 µM) were added
2 h after addition of [14C]PZA to allow
sufficient conversion of PZA to POA. Portions (50 µl) of suspension
were filtered, and the radioactive cells on the membrane were washed
twice with 2 ml of 0.1 M potassium phosphate buffer (pH 7.0) containing
0.1 M LiCl.
 |
RESULTS |
Acidic pH enhances accumulation of POA in M. tuberculosis.
We examined the conversion of PZA to POA and the
accumulation of POA in M. tuberculosis H37Ra by
incubating bacterial cells with [14C]PZA for 16 h under various pH conditions. Culture supernatants and bacterial
lysates were analyzed by TLC followed by autoradiography (Fig.
1). [14C]PZA was
converted to POA, which was not further converted into other
components (Fig. 1). At neutral or alkaline pHs, there was little
POA associated with the bacterial cells and POA was found mainly
in the supernatant. In contrast, at acidic pHs, there was much more
[14C]POA associated with the bacterial cells (Fig.
1), although the conversion of [14C]PZA was somewhat
reduced, judging from the increased amount of unaltered
[14C]PZA in the supernatant. This was apparently due
to acid inhibition of the PZase (data not shown).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 1.
Effect of pH on [14C]PZA conversion in
M. tuberculosis. [14C]PZA was
incubated with M. tuberculosis H37Ra cells for 16 h under various pH conditions. [14C]PZA conversion
and accumulation of [14C]POA by H37Ra in both
supernatant and cell lysate were analyzed by TLC.
|
|
We then tested whether the increased accumulation of POA in the
M. tuberculosis cells under acidic-pH conditions was
due to passive distribution of POA between the bacterial cells
and the medium. Using [14C]POA, we found
that the effect of acidic pH was indeed to enhance the accumulation of
POA (a weak acid with a pKa of 2.9 [3]) in
M. tuberculosis cells and that the POA accumulation was
more pronounced at lower pH values (Fig.
2). This observation is consistent with
the expectation that weak acids are accumulated intracellularly under
acidic-pH conditions because an equilibrium is reached when the
concentration of the uncharged form or conjugate acid, which permeates
through the membrane by passive diffusion, becomes equal on both sides
of the membrane (16, 18). It is noteworthy that there was a
major difference in between POA accumulation at pH 6.6 and that at pH 2 to 5 (Fig. 1 and 2). At pH 6.6, conditions under which PZA has no
antituberculosis activity (26), the POA concentration in the
M. tuberculosis cells was similar to the external
concentration; by contrast, the POA concentrations in the cells at
acidic pH values, conditions under which PZA shows activity, were
several-hundred-fold higher than the external concentration, as
expected from the passive distribution theory (Fig. 1 and 2).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of pH on [14C]POA accumulation
in M. tuberculosis. The accumulation of
[14C]POA by strain H37Ra at various pH values was
monitored at different time points (5, 10, 20, 40, 80, 160, 320, and
1,320 min) after [14C]POA addition at 19 µM (1 µCi/ml). The concentrations of POA in the cells were determined as
described in Materials and Methods and are expressed on a log scale.
|
|
The internal pH.
We measured the internal pH of M. tuberculosis H37Ra cells at an external pH of 5.0, using
[14C]benzoic acid or [14C]salicylic
acid as a probe. The internal pH of H37Ra cells was close to 7 and did not decrease upon exposure to an acidic pH of 5.0 for 5 to 6 h. Addition of salicylate (4 mM) lowered the internal pH
quickly, as expected. POA at 4 mM (500 µg/ml), however, did not
significantly lower the internal pH of the M. tuberculosis cells, probably because at pH 5.0, according to the
Henderson-Hasselbach equation, only 0.8% of the POA is uncharged and
therefore POA crosses the membrane too slowly. When M. tuberculosis H37Ra cells were incubated with PZA at a
concentration of 50 µg/ml for 2 h at pH 5.0, the drug did not
have any significant effect on the internal pH. These data suggest that
the internal pH of living M. tuberculosis cells is
actively maintained at close to 7.
PZA-resistant M. tuberculosis complex organisms do
not accumulate PZA.
Two strains, M. bovis BCG
(which is naturally resistant to PZA due to a mutation at nucleotide
position 169 of the pncA gene [21]) and a
PZA-resistant M. tuberculosis clinical isolate (with a
nucleotide deletion at position 391 of the pncA gene)
(22), were incubated with [14C]PZA.
Neither strain was able to convert [14C]PZA into POA,
as demonstrated by TLC analysis (data not shown). Importantly, the
intracellular concentration of PZA remained similar to the external
concentration (Fig. 3), indicating that
PZA had not accumulated. In contrast, PZA-susceptible M. tuberculosis H37Ra, with a functional PZase, was able to
convert PZA and retained a significant amount of radioactivity (mostly
POA in the cells, as determined by TLC) in the cells even at an
external pH of 6.6 at early time points (Fig. 3).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 3.
Comparison of PZA accumulation in PZA-susceptible and
-resistant M. tuberculosis complex organisms.
[14C]PZA was added to 5 × 109
M. tuberculosis H37Ra or M. bovis BCG
cells at a concentration of 1 µCi/ml at pH 6.6. At various time
points after PZA addition, portions of bacterial cells were removed and
washed by filtration, using phosphate buffer (pH 6.6). The results of a
representative experiment are shown here.
|
|
However, when BCG was transformed with a functional M. tuberculosis or M. avium pncA gene, the
recombinant BCG strains expressed PZase activity, converted PZA to
POA, accumulated POA in bacterial cells at an acidic pH, and became
susceptible to PZA (data not shown). Furthermore, both BCG and the
PZA-resistant M. tuberculosis isolate accumulated
[14C]POA from the external medium at acidic pHs (data
not shown). This result is consistent with the finding that both BCG
and PZA-resistant M. tuberculosis strains are still
susceptible to POA (7).
Localization of PZase in M. tuberculosis.
We
tested the PZase activity in the isolated membrane fraction, the
cytosolic fraction, and the culture supernatant of M. tuberculosis H37Ra. The conventional PZase assay
(29) was very insensitive and failed to detect PZase
activity in these fractions. However, with the more sensitive method
using radioactive [14C]PZA, PZase activity was
mainly found in the cytosolic fraction (data not shown). Similarly,
most PZase activity was located in the cytosolic fraction in
M. smegmatis (data not shown). No PZase activity
was detected in the supernatant fluids of either M. tuberculosis or M. smegmatis cultures. These data
suggest that most PZA conversion occurs in the cytoplasm.
Differences in PZA transport and conversion for PZA-susceptible
M. tuberculosis and naturally resistant mycobacteria
or other bacteria.
The basis for the natural resistance of
nontuberculous mycobacteria to some antituberculosis drugs has often
been suggested to be the impermeability of their cell walls
(4). We compared conversion of [14C]PZA by
susceptible M. tuberculosis with that by the
fast-growing mycobacteria M. smegmatis, and
M. vaccae, as well as a slow-growing mycobacterium,
M. avium, at pH 6.6. Both M. smegmatis
and M. vaccae are highly resistant to PZA (MICs,
>2,000 µg/ml), whereas M. avium has an intermediate
level of susceptibility to PZA (MIC, 500 µg/ml) (23).
These nontuberculous mycobacteria did convert PZA to POA, indicating
that their natural PZA resistance is not due to a defective PZase.
Surprisingly, M. smegmatis and M. vaccae behaved very differently from the susceptible species
M. tuberculosis. Conversion of
[14C]PZA to POA occurred very rapidly in
M. smegmatis, probably due to a higher PZase
activity, as was recently shown by another laboratory (2). However, POA was released into the culture supernatant as soon as [14C]PZA was added to the culture (Fig.
4A). The same rapid release of POA was
also found with M. vaccae (data not shown). We examined whether the rapid appearance of POA in the supernatant of M. smegmatis cultures was due to a secreted PZase. The culture
supernatant did not contain any PZase activity (data not shown).
E. coli, which is also naturally resistant to PZA (MIC,
>2,000 µg/ml) (23), behaved similarly to M. smegmatis and M. vaccae, and all of the [14C]PZA was converted to and released from the cells
as [14C]POA within 45 min (Fig. 4B). In contrast,
M. tuberculosis converted [14C]PZA
slowly, and POA began to appear in the supernatant only after 60 min;
even after 32 h of incubation there was still unaltered [14C]PZA in the supernatant (Fig. 4C).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 4.
Comparison of [14C]PZA conversion and
[14C]POA release among M. smegmatis,
E. coli, and M. tuberculosis. Bacterial cell
suspensions (about 5 × 109 cells/ml) were prepared
from early-stationary-phase cultures and resuspended in an appropriate
medium at pH 6.6. [14C]PZA (1 µCi/ml) was added to
the bacterial suspensions, and the radioactive cell mixtures were
incubated at 37°C for various periods of time up to 1 h for
M. smegmatis (A) and E. coli (B) and up to
32 h for M. tuberculosis H37Ra (C). The extent of
[14C]PZA conversion to [14C]POA in
the supernatant fluids was monitored by TLC.
|
|
In similar [14C]PZA conversion experiments as in Fig.
1, the nonsusceptible species M. smegmatis and
M. vaccae did not accumulate POA in the cells, even
under acidic-pH conditions (data not shown). Consistent with this
observation, when [14C]POA was added to cells at pH
5.5, little POA was found to be associated with the M. smegmatis cells, whereas increasing amounts of externally added
[14C]POA entered into M. tuberculosis
over time (Fig. 5). In the case of
M. avium, both the rate of [14C]PZA
conversion and the amount of [14C]POA associated with
the M. avium cells under acidic pH conditions were
intermediate between the values for M. tuberculosis and
M. smegmatis (data not shown). This finding is
consistent with the intermediate level of susceptibility of
M. avium to PZA (23).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 5.
Differences in POA accumulation between M. tuberculosis (M. tb) and M. smegmatis
(M. smeg). [14C]POA (2.5 µCi/ml) was added to
bacterial suspensions with a density of 5 × 109
cells/ml at an acidic pH of 5.5, and the cells were incubated at 37°C
for various lengths of time up to 7 h. Portions of the bacterial
cell suspensions (50 µl) were removed and washed with Sauton's
medium by filtration under a vacuum. The internal POA concentrations in
the bacterial cells were determined as described in Materials and
Methods.
|
|
POA efflux in M. smegmatis and M. tuberculosis.
POA is expected to be accumulated passively
under acidic-pH conditions, but it did not accumulate in M. smegmatis (Fig. 5); we suspected that this was due to an
active efflux mechanism pumping POA out of the cells. To prove
this, we tested various inhibitors of energy metabolism, including CCCP
(8, 27), nigericin (17), valinomycin
(17), and DCCD (1), as well as reserpine, a plant alkaloid that inhibits the Bacillus subtilis multidrug
efflux pump (15), by incubating M. smegmatis
cells with [14C]PZA at pH 6.6. Interestingly,
reserpine at a sublethal concentration (20 µM) allowed
significant accumulation of POA in M. smegmatis cells
(Fig. 6A), although it inhibited PZA
conversion to some degree because of its inhibition of PZase
activity (data not shown). M. smegmatis cells extruded
POA very rapidly (Fig. 6A). Since at the internal pH of 7 only 0.01%
of the POA is expected to be in the membrane-permeable
uncharged form, this rapid efflux strongly suggests that
M. smegmatis has an active efflux mechanism that pumps out POA, a conclusion also supported by the reserpine inhibition data. Among the energy inhibitors, valinomycin at a sublethal concentration (0.85 to 1 µM) caused significant retention of
[14C]POA in M. smegmatis cells (Fig.
6A).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 6.
Effect of reserpine and valinomycin on accumulation of
POA in M. smegmatis (A) and M. tuberculosis (B). The experiments were performed by adding
[14C]PZA to cells at pH 6.6 as described in Materials
and Methods. Shown are data from a representative experiment.
|
|
To determine whether there is an efflux mechanism for POA in
M. tuberculosis, we tested the effects of reserpine and
valinomycin on the accumulation of [14C]POA in
M. tuberculosis H37Rv by adding
[14C]PZA at pH 6.6. Reserpine caused POA accumulation
in H37Rv cells (Fig. 6B), suggesting that M. tuberculosis also has an active POA efflux mechanism. Valinomycin
also caused significant retention of POA in M. tuberculosis cells (Fig. 6B). However, the rate of POA extrusion
(about 0.3 pmol/mg/min [Fig. 6B]) was more than 2 orders of magnitude
lower than that found in M. smegmatis (about 70 pmol/mg/min [Fig. 6A]).
 |
DISCUSSION |
Despite the importance of PZA in shortening the length of
tuberculosis therapy, its mode of action is unknown. An unusual aspect
of PZA is the requirement of an acidic pH for activity against
M. tuberculosis (11). However, an acidic pH
alone does not directly activate PZA (11), nor does it
induce the M. tuberculosis PZase and hence lead to
more efficient PZA conversion to POA (23). We have shown in
this study that an acidic pH does not cause increased accumulation of
PZA itself (Fig. 1) and that it results in decreased PZA conversion to
some extent through inhibition of PZase activity. Instead, we found
that an acidic pH enhanced the accumulation of POA (the active
derivative of PZA) in M. tuberculosis (Fig. 1 and 2).
This acid-facilitated accumulation of POA and the degree of POA
accumulation in the cells correlate well with the previous finding that
the MICs of PZA for M. tuberculosis decrease at lower pH values (20).
The increased accumulation of POA under acidic-pH conditions could be
due to active transport of POA into the cells. However, a similar
accumulation of POA took place when the compound was generated inside
the cytoplasm (Fig. 1). We believe, therefore, that this is due to the
passive equilibration of POA across the membrane. Any lipophilic, weak
acids spontaneously diffuse through the membrane in their protonated
forms and thus come to equilibrium when the concentrations of
protonated forms become equal on both sides of the cytoplasmic membrane
(16, 18). Since the cytosol in living M. tuberculosis cells is maintained at a pH close to 7 (see Results),
most of POA in the cytoplasm will be in the dissociated form, and the
total concentration of POA here will be more than 1,000-fold higher
than the concentration of protonated POA. In contrast, when the
external pH is acidic
say, pH 2.9
the total concentration of POA in
the external medium will be only twice that of the protonated form. At
equilibrium, the concentrations of protonated POA on both sides will be
equal, with the result being that the total POA concentration in the
cytoplasm is several orders of magnitude higher than that in the
medium at an acidic pH, precisely as observed in Fig. 2. When the pH of
the medium is close to 7, there is little difference in the pH across
the membrane, and there should be no passive accumulation of POA, again
as observed in this study (Fig. 2). This hypothesis predicts that a
decrease of external pH by 1 unit should increase POA accumulation by a
factor of about 10. In Fig. 2, however, the observed increase was only
three- to fourfold. One possible reason for this discrepancy is the
slow, active efflux of POA by M. tuberculosis cells
(see below).
This concept of passive equilibration of POA explains the
observation that PZA is active against M. tuberculosis only at an acidic pH, not at neutral and
alkaline pH values. When M. tuberculosis cells were
incubated with PZA at neutral pH, radioactive POA was found inside the
cells at early time points (Fig. 3 and 6B). This was expected, because
POA was generated by the hydrolysis of PZA, a lipophilic, uncharged
compound that should diffuse rapidly into the cells. Indeed, a
comparison of the H37Ra data in Fig. 3 and 5 shows that PZA diffuses
into cells much more rapidly than does POA. The intracellular POA thus
generated then diffuses spontaneously and also by a slow, active efflux
(see below) out into the medium, because there is no passive retention
of POA under conditions of neutral external pH and because the volume
of external medium is many orders of magnitude larger than the
intracellular volume.
The finding that PZA-resistant TB complex organisms without PZase
activity failed to accumulate or fix [14C]PZA was
somewhat unexpected. Even when closely spaced time points were used, no
accumulation of PZA could be demonstrated inside the
PZase-defective M. bovis BCG cells. The most
plausible explanations for this observation are (i) that PZA, as a
neutral amide, is not accumulated in the cell regardless of the
external pH and (ii) that lipophilic, uncharged PZA passively diffuses
out of the cells during the filtration washing step. In contrast, in PZase-positive, PZA-susceptible M. tuberculosis,
PZA will be converted to POA as it enters the cells and POA will be
trapped inside the cells due to its negative charge. Thus, the PZA
uptake experiment probably does not reflect the actual PZA uptake per
se but rather represents POA accumulation in the cells. In fact, there
was no difference between BCG and H37Ra with regard to PZA accumulation when the bacterial cells were spun through silicone oil (data not
shown). Our observation that PZA-resistant, pncA-defective M. tuberculosis complex strains did not accumulate PZA
is in keeping with the previous finding that E. coli mutants
defective in pncA (encoding nicotinamidase) also failed to
accumulate nicotinamide (13).
The data presented in Fig. 4 show the kinetic differences
in PZA uptake, conversion to POA, and potential POA efflux among various bacteria. We believe that the differences reflect
differences in PZase enzyme activity, POA efflux, and, to a
much lesser extent, cell wall permeability, because PZA is a
neutral amide and should passively diffuse into different cells
relatively easily.
In this study, we found that the naturally PZA-resistant M. smegmatis has a highly active efflux mechanism for POA which can be inhibited by reserpine and valinomycin (Fig. 6A). Although nigericin
and CCCP did not show inhibition, this could be due to the inadequate
entry of these agents through the rather impermeable cell wall or to
their active efflux. The valinomycin effect thus suggests that the pump
is energized by the proton motive force or one of its components.
M. tuberculosis also has a POA efflux mechanism, as
demonstrated by increased accumulation of POA at neutral pH in the
presence of reserpine and valinomycin (Fig. 6B). The M. tuberculosis efflux mechanism is much weaker than that of
M. smegmatis, as evidenced by the
orders-of-magnitude-slower kinetics of POA extrusion (compare Fig. 6B
and A). Thus, in M. tuberculosis, at an acidic external
pH, the rate of passive transmembrane equilibrium of POA apparently
overwhelms that of active efflux, resulting in a huge accumulation of
POA in the cells. The POA efflux mechanism in M. smegmatis appears to be different from the recently identified
M. smegmatis MDR pump LfrA (24), since insertion of the lfrA gene into M. tuberculosis H37Ra did not cause enhanced efflux of POA or
increased resistance to PZA or POA (unpublished data). Studies designed
to identify the POA efflux mechanisms in M. smegmatis
and M. tuberculosis are under way.
While both susceptible M. tuberculosis and other
nonsusceptible mycobacteria have PZases to convert PZA to
POA, the specificity of PZA for M. tuberculosis
appears to be conferred at the stage of POA efflux, which is much
weaker in M. tuberculosis than in the nonsusceptible
M. smegmatis. It is noteworthy that the two types of
PZA resistance, the acquired PZA resistance found in susceptible
M. tuberculosis and the intrinsic PZA resistance found in nontuberculous mycobacteria, are caused by very different
mechanisms. Acquired PZA resistance in susceptible M. tuberculosis is caused by mutations in the pncA gene
which render the organisms unable to convert the prodrug PZA to
bactericidal POA. In contrast, the intrinsic PZA resistance in
M. smegmatis, and probably in many other
nontuberculous mycobacteria, is due to a much more active POA efflux
mechanism which does not allow accumulation of POA in the cells.
 |
ACKNOWLEDGMENTS |
We thank Peter Maloney for helpful discussions; Diane Griffin,
Barbara Laughon, and Denis Mitchison for encouragement; and the
National Institutes of Health (NIH) AIDS Reagents Program for
[14C]pyrazinamide.
This work was supported by research grants from the American Lung
Association, the Potts Memorial Foundation, and NIH (RO1AI40584) to Y.Z.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Molecular Microbiology and Immunology, School of Hygiene and Public
Health, Johns Hopkins University, 615 N. Wolfe St., Baltimore, MD
21205. Phone: (410) 614-2975. Fax: (410) 955-0105. E-mail:
yzhang{at}jhsph.edu.
Present address: Virus Research Institute, Cambridge, MA 02138.
 |
REFERENCES |
| 1.
|
Azzi, A.,
R. P. Casey, and M. J. Nalecz.
1984.
The effect of N,N'-dicyclohexylcarbodiimide on enzymes of bioenergetic relevance.
Biochim. Biophys. Acta
768:209-226[Medline].
|
| 2.
|
Boshoff, H. I. M., and V. Mizrahi.
1998.
Purification, gene cloning, targeted knockout, overexpression, and biochemical characterization of the major pyrazinamidase from Mycobacterium smegmatis.
J. Bacteriol.
180:5809-5814[Abstract/Free Full Text].
|
| 3.
|
Budavari, S.
1989.
The Merck index, 11th ed.
Merck & Co., Inc., Rahway, N.J.
|
| 4.
|
David, H.
1981.
Basis for lack of drug susceptibility of atypical mycobacteria.
Rev. Infect. Dis.
3:878-884[Medline].
|
| 5.
|
Good, R. C.,
V. A. Silcox,
J. O. Kilburn, and B. D. Plikaytis.
1985.
Identification and drug susceptibility test results for Mycobacterium spp.
Clin. Microbiol. Newslett.
7:133-136.
|
| 6.
|
Heifets, L., and P. Lindholm-Levy.
1992.
Pyrazinamide sterilizing activity in vitro against semi-dormant Mycobacterium tuberculosis bacterial populations.
Am. Rev. Respir. Dis.
145:1223-1225[Medline].
|
| 7.
|
Konno, K.,
F. M. Feldman, and W. McDermott.
1967.
Pyrazinamide susceptibility and amidase activity of tubercle bacilli.
Am. Rev. Respir. Dis.
95:461-469[Medline].
|
| 8.
|
Li, X.-Z.,
D. M. Livermore, and H. Nikaido.
1994.
Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin.
Antimicrob. Agents Chemother.
38:1732-1741[Abstract/Free Full Text].
|
| 9.
|
McClatchy, J. K.,
A. Y. Tsang, and M. S. Cernich.
1981.
Use of pyrazinamidase activity in Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility.
Antimicrob. Agents Chemother.
20:556-557[Abstract/Free Full Text].
|
| 10.
|
McCune, R. M.,
R. Tompsett, and W. McDermott.
1956.
The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique.
J. Exp. Med.
104:763-802[Abstract].
|
| 11.
|
McDermott, W., and R. Tompsett.
1954.
Activation of pyrazinamide and nicotinamide in acidic environment in vitro.
Am. Rev. Tuberc.
70:748-754.
[Medline] |
| 12.
|
McKenzie, D.,
L. Malone,
S. Kushner,
J. J. Oleson, and Y. Subbarow.
1948.
The effect of nicotinic acid amide on experimental tuberculosis of white mice.
J. Lab. Clin. Med.
33:1249-1253[Medline].
|
| 13.
|
McLaren, J.,
D. T. C. Ngo, and M. Olivera.
1973.
Pyridine nucleotide metabolism in Escherichia coli.
J. Biol. Chem.
248:5144-5159[Abstract/Free Full Text].
|
| 14.
|
Mitchison, D. A.
1985.
The action of antituberculosis drugs in short course chemotherapy.
Tubercle
66:219-225[Medline].
|
| 15.
|
Neyfakh, A. A.,
V. E. Bidnenko, and L. B. Chen.
1991.
Efflux-mediated multidrug resistance in Bacillus subtilis: similarities and dissimilarities with the mammalian system.
Proc. Natl. Acad. Sci. USA
88:4781-4785[Abstract/Free Full Text].
|
| 16.
|
Nikaido, H., and D. G. Thanassi.
1993.
Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples.
Antimicrob. Agents Chemother.
37:1393-1399[Free Full Text].
|
| 17.
|
Ramos, S.,
S. Schuldiner, and H. R. Kaback.
1976.
The electrochemical gradient of protons and its relationship to active transport in Escherichia coli membrane vesicles.
Proc. Natl. Acad. Sci. USA
73:1892-1896[Abstract/Free Full Text].
|
| 18.
|
Rottenberg, H.
1979.
The measurement of membrane potential and pH in cells, organelles, and vesicles.
Methods Enzymol.
55:547-569[Medline].
|
| 19.
|
Ryan, F.
1993.
The forgotten plague, p. 345-347.
Little, Brown and Company, Boston, Mass.
|
| 20.
|
Salfinger, M., and L. B. Heifets.
1988.
Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method.
Antimicrob. Agents Chemother.
32:1002-1004[Abstract/Free Full Text].
|
| 21.
|
Scorpio, A., and Y. Zhang.
1996.
Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus.
Nat. Med.
2:662-667[Medline].
|
| 22.
|
Scorpio, A.,
P. Lindholm-Levy,
L. Heifets,
R. Gilman,
S. Siddiqi,
M. Cynamon, and Y. Zhang.
1997.
Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.
Antimicrob. Agents Chemother.
41:540-543[Abstract].
|
| 23.
|
Sun, A.,
A. Scorpio, and Y. Zhang.
1997.
The pncA gene from naturally pyrazinamide-resistant Mycobacterium avium encodes pyrazinamidase and confers pyrazinamide susceptibility to resistant M. tuberculosis complex organisms.
Microbiology
143:3367-3373[Medline].
|
| 24.
|
Takiff, H. E.,
M. Cimino,
M. C. Musso,
T. Weisbrod,
R. Martinez,
M. B. Delgado,
L. Salazar,
B. R. Bloom, and W. R. Jacobs.
1996.
Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis.
Proc. Natl. Acad. Sci. USA
93:362-366[Abstract/Free Full Text].
|
| 25.
|
Tarnok, I., and E. Rohrscheidt.
1976.
Biochemical background of some enzymatic tests used for the differentiation of mycobacteria.
Tubercle
57:145-150[Medline].
|
| 26.
|
Tarshis, M. S., and W. A. Weed.
1953.
Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media.
Am. Rev. Tuberc.
67:391-395.
|
| 27.
|
Thanassi, D. G.,
L. W. Cheng, and H. Nikaido.
1997.
Active efflux of bile salts by Escherichia coli.
J. Bacteriol.
179:2512-2518[Abstract/Free Full Text].
|
| 28.
|
Trivedi, S. S., and S. G. Desai.
1987.
Pyrazinamidase activity of Mycobacterium tuberculosis a test of sensitivity to pyrazinamide.
Tubercle
68:221-224[Medline].
|
| 29.
|
Wayne, L. G.
1974.
Simple pyrazinamidase and urease tests for routine identification of mycobacteria.
Am. Rev. Respir. Dis.
109:147-151[Medline].
|
| 30.
|
World Health Organization.
1995.
WHO report on the tuberculosis epidemic: stop TB at the source.
Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
|
| 31.
|
Youatt, J., and S. H. Tham.
1969.
Radioactive content of Mycobacterium tuberculosis after exposure to 14C-isoniazid.
Am. Rev. Respir. Dis.
100:77-78[Medline].
|
| 32.
|
Zhang, Y.,
B. Heym,
B. Allen,
D. Young, and S. Cole.
1992.
The catalase-peroxidase and isoniazid resistance in Mycobacterium tuberculosis.
Nature
358:591-593[Medline].
|
Journal of Bacteriology, April 1999, p. 2044-2049, Vol. 181, No. 7
0021-9193/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Mphahlele, M., Syre, H., Valvatne, H., Stavrum, R., Mannsaker, T., Muthivhi, T., Weyer, K., Fourie, P. B., Grewal, H. M. S.
(2008). Pyrazinamide Resistance among South African Multidrug-Resistant Mycobacterium tuberculosis Isolates. J. Clin. Microbiol.
46: 3459-3464
[Abstract]
[Full Text]
-
Gu, P., Constantino, L., Zhang, Y.
(2008). Enhancement of the antituberculosis activity of weak acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids act differently from the front-line tuberculosis drug pyrazinamide. J Med Microbiol
57: 1129-1134
[Abstract]
[Full Text]
-
Boshoff, H. I. M., Xu, X., Tahlan, K., Dowd, C. S., Pethe, K., Camacho, L. R., Park, T.-H., Yun, C.-S., Schnappinger, D., Ehrt, S., Williams, K. J., Barry, C. E. III
(2008). Biosynthesis and Recycling of Nicotinamide Cofactors in Mycobacterium tuberculosis: AN ESSENTIAL ROLE FOR NAD IN NONREPLICATING BACILLI. J. Biol. Chem.
283: 19329-19341
[Abstract]
[Full Text]
-
Martin, A., Cubillos-Ruiz, A., Von Groll, A., Del Portillo, P., Portaels, F., Palomino, J. C.
(2008). Nitrate reductase assay for the rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J Antimicrob Chemother
61: 123-127
[Abstract]
[Full Text]
-
Ngo, S. C., Zimhony, O., Chung, W. J., Sayahi, H., Jacobs, W. R. Jr., Welch, J. T.
(2007). Inhibition of Isolated Mycobacterium tuberculosis Fatty Acid Synthase I by Pyrazinamide Analogs. Antimicrob. Agents Chemother.
51: 2430-2435
[Abstract]
[Full Text]
-
Zimhony, O., Vilcheze, C., Arai, M., Welch, J. T., Jacobs, W. R. Jr.
(2007). Pyrazinoic Acid and Its n-Propyl Ester Inhibit Fatty Acid Synthase Type I in Replicating Tubercle Bacilli. Antimicrob. Agents Chemother.
51: 752-754
[Abstract]
[Full Text]
-
Singh, P., Wesley, C., Jadaun, G. P. S., Malonia, S. K., Das, R., Upadhyay, P., Faujdar, J., Sharma, P., Gupta, P., Mishra, A. K., Singh, K., Chauhan, D. S., Sharma, V. D., Gupta, U. D., Venkatesan, K., Katoch, V. M.
(2007). Comparative Evaluation of Lowenstein-Jensen Proportion Method, BacT/ALERT 3D System, and Enzymatic Pyrazinamidase Assay for Pyrazinamide Susceptibility Testing of Mycobacterium tuberculosis. J. Clin. Microbiol.
45: 76-80
[Abstract]
[Full Text]
-
Wade, M. M., Zhang, Y.
(2006). Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro. J Antimicrob Chemother
58: 936-941
[Abstract]
[Full Text]
-
Barco, P., Cardoso, R. F., Hirata, R. D. C., Leite, C. Q. F., Pandolfi, J. R., Sato, D. N., Shikama, M. L., de Melo, F. F., Mamizuka, E. M., Campanerut, P. A. Z., Hirata, M. H.
(2006). pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. J Antimicrob Chemother
58: 930-935
[Abstract]
[Full Text]
-
Hanoulle, X., Wieruszeski, J.-M., Rousselot-Pailley, P., Landrieu, I., Locht, C., Lippens, G., Baulard, A. R.
(2006). Selective intracellular accumulation of the major metabolite issued from the activation of the prodrug ethionamide in mycobacteria. J Antimicrob Chemother
58: 768-772
[Abstract]
[Full Text]
-
Martin, A., Takiff, H., Vandamme, P., Swings, J., Palomino, J. C., Portaels, F.
(2006). A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J Antimicrob Chemother
58: 327-331
[Abstract]
[Full Text]
-
Ren, H., Liu, J.
(2006). AsnB Is Involved in Natural Resistance of Mycobacterium smegmatis to Multiple Drugs. Antimicrob. Agents Chemother.
50: 250-255
[Abstract]
[Full Text]
-
Denkin, S., Volokhov, D., Chizhikov, V., Zhang, Y.
(2005). Microarray-based pncA genotyping of pyrazinamide-resistant strains of Mycobacterium tuberculosis. J Med Microbiol
54: 1127-1131
[Abstract]
[Full Text]
-
Singh, A., Gupta, R., Vishwakarma, R. A., Narayanan, P. R., Paramasivan, C. N., Ramanathan, V. D., Tyagi, A. K.
(2005). Requirement of the mymA Operon for Appropriate Cell Wall Ultrastructure and Persistence of Mycobacterium tuberculosis in the Spleens of Guinea Pigs. J. Bacteriol.
187: 4173-4186
[Abstract]
[Full Text]
-
Tran, S. L., Rao, M., Simmers, C., Gebhard, S., Olsson, K., Cook, G. M.
(2005). Mutants of Mycobacterium smegmatis unable to grow at acidic pH in the presence of the protonophore carbonyl cyanide m-chlorophenylhydrazone. Microbiology
151: 665-672
[Abstract]
[Full Text]
-
Wade, M. M., Zhang, Y.
(2004). Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. J Med Microbiol
53: 769-773
[Abstract]
[Full Text]
-
Somoskovi, A., Wade, M. M., Sun, Z., Zhang, Y.
(2004). Iron enhances the antituberculous activity of pyrazinamide. J Antimicrob Chemother
53: 192-196
[Abstract]
[Full Text]
-
Zhang, Y., Wade, M. M., Scorpio, A., Zhang, H., Sun, Z.
(2003). Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother
52: 790-795
[Abstract]
[Full Text]
-
Zhang, Y., Zhang, H., Sun, Z.
(2003). Susceptibility of Mycobacterium tuberculosis to weak acids. J Antimicrob Chemother
52: 56-60
[Abstract]
[Full Text]
-
Kim, S., Watarai, M., Kondo, Y., Erdenebaatar, J., Makino, S.-i., Shirahata, T.
(2003). Isolation and Characterization of Mini-Tn5Km2 Insertion Mutants of Brucella abortus Deficient in Internalization and Intracellular Growth in HeLa Cells. Infect. Immun.
71: 3020-3027
[Abstract]
[Full Text]
-
Kaatz, G. W., Moudgal, V. V., Seo, S. M., Kristiansen, J. E.
(2003). Phenothiazines and Thioxanthenes Inhibit Multidrug Efflux Pump Activity in Staphylococcus aureus. Antimicrob. Agents Chemother.
47: 719-726
[Abstract]
[Full Text]
-
Gerdes, S. Y., Scholle, M. D., D'Souza, M., Bernal, A., Baev, M. V., Farrell, M., Kurnasov, O. V., Daugherty, M. D., Mseeh, F., Polanuyer, B. M., Campbell, J. W., Anantha, S., Shatalin, K. Y., Chowdhury, S. A. K., Fonstein, M. Y., Osterman, A. L.
(2002). From Genetic Footprinting to Antimicrobial Drug Targets: Examples in Cofactor Biosynthetic Pathways. J. Bacteriol.
184: 4555-4572
[Abstract]
[Full Text]
-
Takii, T., Yamamoto, Y., Chiba, T., Abe, C., Belisle, J. T., Brennan, P. J., Onozaki, K.
(2002). Simple Fibroblast-Based Assay for Screening of New Antimicrobial Drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother.
46: 2533-2539
[Abstract]
[Full Text]
-
Boshoff, H. I., Mizrahi, V., Barry, C. E. III
(2002). Effects of Pyrazinamide on Fatty Acid Synthesis by Whole Mycobacterial Cells and Purified Fatty Acid Synthase I. J. Bacteriol.
184: 2167-2172
[Abstract]
[Full Text]
-
ZHANG, Y., PERMAR, S., SUN, Z.
(2002). Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol
51: 42-49
[Abstract]
[Full Text]
-
Rao, M., Streur, T. L., Aldwell, F. E., Cook, G. M.
(2001). Intracellular pH regulation by Mycobacterium smegmatis and Mycobacterium bovis BCG. Microbiology
147: 1017-1024
[Abstract]
[Full Text]
-
Boshoff, H. I. M., Mizrahi, V.
(2000). Expression of Mycobacterium smegmatis Pyrazinamidase in Mycobacterium tuberculosis Confers Hypersensitivity to Pyrazinamide and Related Amides. J. Bacteriol.
182: 5479-5485
[Abstract]
[Full Text]
-
Guo, M., Sun, Z., Zhang, Y.
(2000). Mycobacterium smegmatis Has Two Pyrazinamidase Enzymes, PncA and PzaA. J. Bacteriol.
182: 3881-3884
[Abstract]
[Full Text]
-
Cheng, S.-J., Thibert, L., Sanchez, T., Heifets, L., Zhang, Y.
(2000). pncA Mutations as a Major Mechanism of Pyrazinamide Resistance in Mycobacterium tuberculosis: Spread of a Monoresistant Strain in Quebec, Canada. Antimicrob. Agents Chemother.
44: 528-532
[Abstract]
[Full Text]
-
Sun, Z., Zhang, Y.
(1999). Spent Culture Supernatant of Mycobacterium tuberculosis H37Ra Improves Viability of Aged Cultures of This Strain and Allows Small Inocula To Initiate Growth. J. Bacteriol.
181: 7626-7628
[Abstract]
[Full Text]